Global Human Microbiome Research Industry is Expecting Major Technological Makeover by 2027

 Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease.

This market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5 % during the forecast period.

The therapeutics segment to account for the largest share of the market in 2022

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

The infectious diseases segment to account for the largest share of the market in 2022

Based on disease, the human microbiome market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.

Recent Developments:

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn’s disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.

# In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.

Europe to account for the largest share of the human microbiome market in 2022

On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.

Key questions addressed by the report:

# Who are the major market players in the human microbiome market?
# What are the regional growth trends and the largest revenue-generating regions for the market?
# What are the major drivers and challenges in the market?
# What are the major product segments in the market?
# What are the major technologies used in the human microbiome research spending market?

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Global Industry Leaders:

The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.

Human Microbiome Research - Here's Whats Trending in the Global Market

Rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate are driving the growth of the human microbiome market. The human microbiome market is an emerging market with abundant opportunities and is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase. In this report, the global human microbiome market is divided into three major segments namely, application, disease, and product.

Restraints:
# Lack of Expertise and Detailed Research
# Barriers in Proving the Causal Link Between Dysbiosis and Disease

You Can Get the Sample Pages for More Information@ https://bit.ly/2wPT6V9

Opportunities:
# Investigational New Drug (IND) Requirements for Fecal Microbiota
# Increasing Collaborations Create Growth Opportunities

Challenge:
# Government Regulations

Burning Issues:
# Abundant Opportunities in the Human Microbiome Field and Tremendous Research Investments.
# Development of Human Microbiome Therapeutic Products

Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.

Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors. Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions. The company provides products and technologies in the emerging areas of disease management for human gut microbiome and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel disease, metabolic diseases, and related disorders.

Read the Detailed Research Report@ https://bit.ly/2w1RJSn

In-depth research into the human microbiome market revealed that agreements, partnerships, and collaborations were the key strategies adopted by major players to enter the microbiome business or expand their microbiome business units.

Major players that adopted this strategy include Second Genome (U.S.), Enterome Bioscience (France), Vedanta Bioscience (U.S.), and Osel, Inc. (U.S.). In April 2016, Enterome entered an agreement with Vertex Pharmaceuticals Inc. (U.S.) to research, develop, and commercialize novel small molecule FimH antagonists, to be utilized in the treatment of inflammatory bowel diseases (IBD).

Companies in the Asia-Pacific regions are also entering the field of microbiome. Yakult Honsha Co., Ltd. is one such company which is engaged in manufacturing and marketing food and beverage products. The company operates through three business segments, namely, Food and Beverages, Pharmaceuticals, and Others. The Food and Beverages segment includes juices, soft drinks, and healthy foods. This segment also includes probiotic drinks that contain Lactobacillus casei, a bacterium which improves intestinal function and immunity.

Europe is expected to command as a resourceful market with the largest share in the human microbiome market and expected to grow within the coming years. This is due to Europe’s aging population size and the increasing lifestyle diseases, followed by the increasing need to stay fit and have a healthy lifestyle has leveraged the use of prebiotics and probiotics. APAC accounted for the second-largest market share and will be the main focus of the market in the coming five years that will register high-growth rates for all the segments.

The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), and ViThera Pharmaceuticals (U.S.)